Ligand validation:4O2B

IMD: IMIDAZOLE

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
4O2B_IMD_C_509	64%	74%	0.14	0.937	0.41	0.59	-	-	0	0	100%	1
4O2B_IMD_C_510	24%	75%	0.246	0.879	0.42	0.56	-	-	0	0	100%	1
4O2B_IMD_C_511	21%	75%	0.204	0.812	0.42	0.57	-	-	0	0	100%	1
5OSK_IMD_C_506	85%	76%	0.079	0.942	0.45	0.5	-	-	0	0	100%	1
5XAG_IMD_C_508	44%	76%	0.182	0.909	0.45	0.51	-	-	2	0	100%	1
5XAF_IMD_E_201	21%	80%	0.242	0.849	0.4	0.45	-	-	1	0	100%	1
4RS3_IMD_A_413	100%	61%	0.034	0.994	0.77	0.71	-	-	0	0	100%	1
3U9W_IMD_A_2009	100%	54%	0.038	0.985	0.43	1.32	-	1	0	0	100%	1
3NN1_IMD_B_243	99%	76%	0.049	0.986	0.35	0.59	-	-	0	0	100%	1
1W8K_IMD_A_1476	99%	44%	0.042	0.978	0.79	1.36	-	1	0	0	100%	1
2ASN_IMD_X_202	99%	67%	0.051	0.987	0.4	0.87	-	-	1	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.